eMedicine Specialties > Urology > Cancer, Prostate
Prostate Cancer - Radical Retropubic Prostatectomy
Updated: Apr 27, 2009
Introduction
Adenocarcinoma of the prostate is the most commonly diagnosed cancer and the second leading cause of death in American males. The recent surge in the incidence of prostate cancer is most likely due to the use of the serum prostate-specific antigen (PSA) test, which has also changed trends in clinical and pathologic features of prostate cancer. PSA testing offers earlier detection, meaning that patients with known prostate cancer are increasingly younger and have earlier-stage, clinically localized disease. As a result, more patients have potentially curable lesions and can benefit from radical prostatectomy.
Recently, the use of minimally invasive radical prostatectomy, particularly robotic prostatectomy, has surged. These new approaches provide excellent visualization of the anatomy and have resulted in less pain and earlier discharge, with equivalent oncologic efficacy. However, even in this era, a sound and fundamental knowledge of traditional open radical prostatectomy, with and without nerve-sparing, is crucial to the urologist's armamentarium.
History of the Procedure
In 1947, Millin introduced the retropubic approach to prostatectomy. The operation had distinct advantages over perineal prostatectomy in that (1) urologists were more familiar with the retropubic anatomy and that (2) the retropubic approach permits the ability to perform an extraperitoneal pelvic lymph node dissection for staging purposes.
During the past decade, modifications in the technique of radical retropubic prostatectomy and the introduction of the anatomic nerve-sparing method have dramatically decreased the frequency of the most concerning associated morbidities—incontinence and impotence.
Walsh deserves much credit for pioneering the technique of nerve-sparing radical retropubic prostatectomy.1 Prior to anatomic characterization in the early 1980s and the description and anatomic characterization of the Santorini plexus, the operation was fraught with massive blood loss and morbidity.
Problem
Prostate cancer is the second most common malignancy in males after cutaneous malignancies and is the second most common cause of cancer death among men in the United States. Prostate cancer is predominantly a disease of elderly men, and the absolute number of cases is expected to increase as worldwide life expectancy increases.
Frequency
Each day in the United States, more than 100 men die of prostate cancer. According to American Cancer Society (ACS) estimates, in 2007, 218,890 men will be newly diagnosed with prostate cancer and 27,050 men will die from the disease.2
The incidence of prostate cancer varies throughout the world but is generally higher in Western developed countries. To illustrate, African American men (in whom the incidence of prostate cancer is highest) are 200 times as likely to develop prostate cancer as are Chinese men living in Asia, in whom the incidence of prostate cancer is among the lowest in the world.
Migration studies have revealed increased prostate cancer rates among migrants who move from areas with low prevalence to areas of high prevalence. In one study, the incidence of prostate cancer in emigrants from Japan increased 4-9 times over the incidence in Japan.3
Etiology
Migration studies suggest that environmental factors (eg, diet) play an important role in prostate cancer (see Prostate Cancer: Nutrition). Researchers have found a positive correlation between higher fat consumption, especially animal fat, and a higher prostate-cancer death rate. Higher fat consumption can increase the relative risk by a factor of 1.6-1.9.
Experts suggest certain dietary habits to lower the risk of prostate cancer. These include a low-fat, high-fiber diet, which lowers serum androgen levels. Researchers have investigated other dietary factors, including selenium, lycopene, vitamin D, alpha-tocopherol, vitamin E, and large amounts of green tea and have postulated that these factors may prevent prostate cancer.
Family history and genetics are important in the etiology of prostate cancer. Having a single first-degree relative with prostate cancer increases the prostate-cancer risk by a factor of 2.1-2.8. Having both a first-degree and a second-degree relative with prostate cancer increases the risk by a factor of 6. Familial predisposition can be due to common environmental exposures; recently, however, researchers mapped a potential major prostate cancer susceptibility locus (1q24-25). This gene, called HPC1, is involved in 33% of hereditary prostate-cancer cases.
Men with a family history of female breast cancer are also at an increased risk of prostate cancer. Specific mutations of BRCA1 and BRCA2, 2 genes involved in familial breast cancers, appear to confer an increased risk for prostate cancer.
Presentation
Before the advent of PSA testing, more cases of prostate cancer were detected at a more advanced stage. Today, most prostate cancers are detected with PSA testing, which has resulted in more cases of prostate cancer being detected earlier, at a lower stage, and organ-confined.
Over the past 10 years, the number of radical prostatectomies performed for clinically localized prostate cancer has risen. Most of this increase is due to the higher number of surgeries performed for c-T1c disease.
The detection of organ-confined prostate cancer has increased through PSA-based screening of asymptomatic men; most tumors detected have clinical and pathologic features of clinically important prostate cancer.Despite the apparent survival advantage of early diagnosis conferred by PSA screening, a recent U.S. Preventive Services Task Force statement recommends against screening for prostate cancer in men aged 75 years or older. The statement also concludes that, currently, the balance of benefits versus drawbacks of prostate cancer screening in men younger than age 75 years cannot be assessed because of insufficient evidence.4
Indications
Currently, nerve-sparing radical retropubic prostatectomy remains a reasonable treatment option for men with clinically localized prostate cancer who have at least a 10-year life expectancy and low comorbidities. It is a well-tolerated procedure that is associated with low morbidity. The procedure is not limited to men younger than a certain age, but the authors generally do not consider patients older than 73 years for prostatectomy. The authors believe that cases have to be judged on an individual basis, but, in an elderly patient with prostate cancer who has alternatives to major surgery and in whom a 10-year overall survival is improbable, justifying a major operation is difficult.
Although the optimal management of higher-stage disease is controversial, radical prostatectomy remains a viable treatment option in T3 disease for select patients. In patients with poorly differentiated disease, surgery can be supplemented with adjuvant hormonal therapy because monotherapy, in any form, is fraught with failure (see Prostate Cancer: Neoadjuvant Androgen Deprivation). Amling et al (1998) reported the Mayo Clinic experience with radical prostatectomy in clinical T3 disease.5 Some cases of prostate cancer are clinically overstaged and can be cured with surgery alone. The remaining patients with locally advanced disease are identified and can be offered adjuvant therapy (see Outcome and Prognosis).
Relevant Anatomy
Physicians must have a clear understanding of the anatomy pertinent to radical prostatectomy. The understanding of periprostatic anatomy, achievement of vascular control, and preservation of the neurovascular bundles allow a safe and anatomic approach to the operation, with reduced morbidity.
- The fascial investment of the bladder and the prostate, the endopelvic fascia (ie, pelvic fascia), sweeps down and off the pelvic sidewall, where it covers the levator ani muscle.
- The puboprostatic ligaments represent the anterior condensation of the fusion of the parietal and visceral pelvic fascia.
- Incising the fascia at this point of fusion exposes the lateral surface of the prostate and the anterolateral rectal wall. At this point, the lateral periprostatic or lateral prostatic fascia becomes evident. This layer continues posteriorly to cover the neurovascular bundles and to become the lateral rectal fascia, and it continues distally over the membranous urethra to become the lateral periurethral fascia.
- The lateral periprostatic fascia is continuous with the endopelvic fascia and is fused to the anterior and posterior Denonvilliers fascia. The rectal fascia (ie, posterior Denonvilliers fascia) covers the anterior surface of the rectum. The neurovascular bundles are invested in this posterior layer of Denonvilliers fascia laterally and are posterior and lateral to the prostate.
- Anterior and posterior leaflets of the anterior Denonvilliers fascia envelop the seminal vesicles. Entering the posterior aspect of the anterior Denonvilliers fascia is essential for the complete dissection of the seminal vesicles in radical retropubic prostatectomy for localized prostate cancer.
- The prostatic plexus of veins (ie, Santorini plexus) carries the venous return from the deep dorsal vein of the penis and the cavernosal veins. These venous effluents ultimately drain into the internal iliac veins.
- The venous drainage may vary greatly and may be asymmetric. Take care in the dissection, especially at the prostate apex, where blood loss could be massive. The superficial branch lies within the retropubic fat, between the puboprostatic ligaments.
- The periphery of the glandular elements of the prostatic peripheral zone contains a fibromuscular rim referred to as the prostatic capsule. The base or apex of the prostate has no well-defined capsule. Here, the capsule is deficient as it merges with the smooth muscle of the bladder neck and with the striated muscle of the urethral sphincter.
- The striated urethral sphincter is directly beneath the dorsal venous complex. This sphincter is well-developed anterolaterally, creating a horseshoe-shaped appearance. Because the striated sphincter mechanism lies directly beneath the dorsal venous complex, take care not to damage its fibers during vein control.
- The cavernous nerves originate from the pelvic plexus on either side of the rectum. They travel posterolaterally to the prostate beneath the cover of the lateral periprostatic fascia. At the level of the membranous urethra, these nerves course anteriorly and lie directly lateral to the urethra. Branches of the nerves are located anteriorly close to the vessels of the penile hilum at the base of the membranous urethra, where the striated sphincter ends.
- Recent experience with robotic and laparoscopic radical prostatectomy has led to the identification and characterization of the vesicoprostatic muscle. This retrotrigonal layer marks the posterior limit of dissection lying anterior to the ejaculatory organs. This layer corresponds with the posterior longitudinal fascia of the detrusor muscle and is divided after the division of the bladder neck posteriorly, just before encountering the ampullae of the vas deferens. The description of this layer challenges the once-common belief that this is actually a layer of the anterior Denonvilliers fascia.
Contraindications
All patients selected for nerve-sparing radical retropubic prostatectomy should have low comorbidities, at least a 10-year life expectancy, and clinically localized disease. Patients with locally advanced disease cannot undergo the nerve-sparing operation; because of the extent of the local tumor burden (especially posteriorly), the nerve-sparing procedure can compromise the adequacy of the operation.
Whether patients with preoperative erectile dysfunction can benefit from nerve-sparing procedures in the sildenafil era has not been extensively studied. Therefore, the authors still do not recommend the nerve-sparing approach in patients with preoperative erectile dysfunction.
The nerve-sparing operation should not be attempted to treat locally advanced prostate cancer. In that setting, the radical prostatectomy specimen should include both layers of Denonvilliers fascia, with a wide excision of the lateral pelvic fascia and the neurovascular bundles en bloc with the prostate and ejaculatory organs.
More on Prostate Cancer - Radical Retropubic Prostatectomy |
 Overview: Prostate Cancer - Radical Retropubic Prostatectomy |
| Workup: Prostate Cancer - Radical Retropubic Prostatectomy |
| Treatment: Prostate Cancer - Radical Retropubic Prostatectomy |
| Follow-up: Prostate Cancer - Radical Retropubic Prostatectomy |
| Multimedia: Prostate Cancer - Radical Retropubic Prostatectomy |
| References |
| Further Reading |
| Next Page » |
References
Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. Sep 1982;128(3):492-7. [Medline].
American Cancer Society. Cancer facts and Figures 2007.
Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. Jun 1991;63(6):963-6. [Medline].
[Best Evidence] U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. Aug 5 2008;149(3):185-91. [Medline].
Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. May 1998;73(5):401-6. [Medline].
Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol. Feb 1991;145(2):313-8. [Medline].
Levran Z, Gonzalez JA, Diokno AC, Jafri SZ, Steinert BW. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?. Br J Urol. Jun 1995;75(6):778-81. [Medline].
Kahn D, Williams RD, Seldin DW, Libertino JA, Hirschhorn M, Dreicer R, et al. Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol. Nov 1994;152(5 Pt 1):1490-5. [Medline].
Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. May 14 1997;277(18):1445-51. [Medline].
Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. Nov 2000;164(5):1591-5. [Medline].
Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. May 20 1998;90(10):766-71. [Medline].
Kattan MW. Should physicians use the updated Partin tables to predict pathologic stage in patients with prostate cancer?. Nat Clin Pract Urol. Nov 2007;4(11):592-3. [Medline].
Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol. Jun 2004;171(6 Pt 1):2255-9. [Medline].
Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. Oct 1997;158(4):1441-5. [Medline].
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. May 5 1999;281(17):1591-7. [Medline].
Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. Aug 1999;162(2):433-8. [Medline].
Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology. Jan 2000;55(1):58-61. [Medline].
Quinlan DM, Epstein JI, Carter BS, Walsh PC. Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol. May 1991;145(5):998-1002. [Medline].
Zippe CD, Jhaveri FM, Klein EA, Kedia S, Pasqualotto FF, Kedia A, et al. Role of Viagra after radical prostatectomy. Urology. Feb 2000;55(2):241-5. [Medline].
Marks LS, Duda C, Dorey FJ, Macairan ML, Santos PB. Treatment of erectile dysfunction with sildenafil. Urology. Jan 1999;53(1):19-24. [Medline].
Nandipati K, Raina R, Agarwal A, Zippe CD. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res. Sep-Oct 2006;18(5):446-51. [Medline].
Zagaja GP, Mhoon DA, Aikens JE, Brendler CB. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology. Oct 1 2000;56(4):631-4. [Medline].
Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. Jun 1 2007;109(11):2239-47. [Medline].
Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. Jun 2007;177(6):2151-6; discussion 2156. [Medline].
Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. Sep 1999;54(3):503-8. [Medline].
Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology. May 2000;55(5):736-42. [Medline].
Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. Nov 1994;152(5 Pt 2):1850-7. [Medline].
Ghavamian R, Blute ML, Bergstralh EJ, et al. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology. Jul 1999;54(1):105-10. [Medline].
Boxer RJ, Kaufman JJ, Goodwin WE. Radical prostatectomy for carcinoma of the prostate: 1951-1976. A review of 329 patients. J Urol. Feb 1977;117(2):208-13. [Medline].
Elder JS, Jewett HJ, Walsh PC. Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate. J Urol. Apr 1982;127(4):704-6. [Medline].
Gomella LG, Liberman SN, Mulholland SG, Petersen RO, Hyslop T, Corn BW. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Urology. Jun 1996;47(6):870-7. [Medline].
Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol. Jan 1996;155(1):213-9. [Medline].
Amling CL, Blute ML, Bergstralh EJ, Slezak JM, Martin SK, Zincke H. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol. Nov 1997;15(4):222-9. [Medline].
Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. Apr 2000;163(4):1178-82. [Medline].
Valicenti RK, Gomella LG, Ismail M, Strup SE, Mulholland SG, Dicker AP, et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. Aug 1 1999;45(1):53-8. [Medline].
Obek C, Sadek S, Lai S, Civantos F, Rubinowicz D, Soloway MS. Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology. Oct 1999;54(4):682-8. [Medline].
Blute ML, Bostwick DG, Bergstralh EJ, Slezak JM, Martin SK, Amling CL, et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. Nov 1997;50(5):733-9. [Medline].
Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. Dec 9 1999;341(24):1781-8. [Medline].
Ghavamian R, Knoll A, Boczko J, Melman A. Comparison of operative and functional outcomes of laparoscopic radical prostatectomy and radical retropubic prostatectomy: single surgeon experience. Urology. 2006;67:1241-6.
Schuessler WW, Schulam PG, Clayman RV, Kavoussi LR. Laparoscopic radical prostatectomy: initial short-term experience. Urology. Dec 1997;50(6):854-7. [Medline].
Tewari A, El-Hakim A, Rao S, Raman JD. Identification of the retrotrigonal layer as a key anatomical landmark during robotically assisted radical prostatectomy. BJU Int. Oct 2006;98(4):829-32. [Medline].
Patel VR, Thaly R, Shah K. Robotic radical prostatectomy: outcomes of 500 cases. BJU Int. May 2007;99(5):1109-12. [Medline].
Amling CL, Leibovich BC, Lerner SE, Bergstralh EJ, Blute ML, Myers RP, et al. Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol. Nov 1997;15(4):215-21. [Medline].
Blute ML, Zincke H. Incidental adenocarcinoma of the prostate: implications and therapeutic strategy. In: Rous S, ed. Urology Annual 1995. Vol 9. New York, NY: WW Norton & Co; 1995:51-7.
Bocchicchio T, Fair WR. Nutrition and cancer of the prostate. AUA Update Series. 1999;18:Lesson 38.
Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. Sep 2007;178(3 Pt 1):864-70; discussion 870-1. [Medline].
Brown JA, Dahl DM. Transperitoneal laparoscopic radical prostatectomy in patients after laparoscopic prosthetic mesh inguinal herniorrhaphy. Urology. Feb 2004;63(2):380-2. [Medline].
Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. Aug 25 1993;270(8):948-54. [Medline].
Eastham JA. Surgery Insight: optimizing open nerve-sparing radical prostatectomy techniques for improved outcomes. Nat Clin Pract Urol. Oct 2007;4(10):561-9. [Medline].
Epstein JI, Oesterling JE, Walsh PC. The volume and anatomical location of residual tumor in radical prostatectomy specimens removed for stage A1 prostate cancer. J Urol. May 1988;139(5):975-9. [Medline].
Geary ES, Dendinger TE, Freiha FS, Stamey TA. Nerve sparing radical prostatectomy: a different view. J Urol. Jul 1995;154(1):145-9. [Medline].
Ghavamian R, Zincke H. An updated simplified approach to nerve-sparing radical retropubic prostatectomy. BJU Int. Jul 1999;84(1):160-3. [Medline].
Ghavamian R, Zincke H. Technique for nerve dissection. Semin Urol Oncol. Feb 2000;18(1):43-5. [Medline].
Ichioka K, Yoshimura K, Utsunomiya N, Ueda N, Matsui Y, Terai A, et al. High incidence of inguinal hernia after radical retropubic prostatectomy. Urology. Feb 2004;63(2):278-81. [Medline].
Janoff DM, Parra RO. Contemporary appraisal of radical perineal prostatectomy. J Urol. Jun 2005;173(6):1863-70. [Medline].
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. Jan-Feb 1999;49(1):8-31, 1. [Medline].
Lange PH. PROSTASCINT scan for staging prostate cancer. Urology. Mar 2001;57(3):402-6. [Medline].
Leandri P, Rossignol G, Gautier JR, Ramon J. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol. Mar 1992;147(3 Pt 2):883-7. [Medline].
Lerner SE, Blute ML, Lieber MM, Zincke H. Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Oncology (Williston Park). May 1995;9(5):379-82; discussion 382, 385-6, 389. [Medline].
Machtens S, Serth J, Meyer A, Kleinhorst C, Ommer KJ, Herbst U. Positron emission tomography (PET) in the urooncological evaluation of the small pelvis. World J Urol. Aug 2007;25(4):341-9. [Medline].
Marks RA, Koch MO, Lopez-Beltran A, Montironi R, Juliar BE, Cheng L. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol. Aug 2007;38(8):1207-11. [Medline].
Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. Jun 2006;7(6):472-9. [Medline].
Myers RP. Male urethral sphincteric anatomy and radical prostatectomy. Urol Clin North Am. May 1991;18(2):211-27. [Medline].
Nandipati K, Raina R, Agarwal A, Zippe CD. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res. Sep-Oct 2006;18(5):446-51. [Medline].
Perrotti M, Pantuck A, Rabbani F, Israeli RS, Weiss RE. Review of staging modalities in clinically localized prostate cancer. Urology. Aug 1999;54(2):208-14. [Medline].
Secin FP, Karanikolas N, Gopalan A, Bianco FJ, Shayegan B, Touijer K, et al. The anterior layer of Denonvilliers' fascia: a common misconception in the laparoscopic prostatectomy literature. J Urol. Feb 2007;177(2):521-5. [Medline].
Stanford J, Stephenson R, Coyle L. Prostate cancer trends 1973-1995, Bethesda, MD, SEER Program. National Cancer Institute. 1998.
Zincke H, Blute ML, Fallen MJ, Farrow GM. Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J Urol. Oct 1991;146(4):1053-8. [Medline].
Keywords
radical retropubic prostatectomy, RRP, robotic-assisted laparoscopic radical prostatectomy, RALP, prostate cancer, prostate-specific antigen, PSA, adenocarcinoma of the prostate, perineal prostatectomy, urinary incontinence, impotence, erectile dysfunction, prostatic adenocarcinoma, prostate adenocarcinoma, radical prostatectomy, minimally invasive radical prostatectomy, robotic prostatectomy, laparoscopic radical prostatectomy
